Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm

Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti–tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries

(2017) Ignacio Garcia-Doval et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Inclusion and exclusion criteria in phase III trials with systemic agents in psoriasis: the external validity of drug development

(2016) N. Kirsten et al.   BRITISH JOURNAL OF DERMATOLOGY

Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest

(2015) K. Reich et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

(2015) Richard B. Warren et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study

(2015) Whan B. Kim et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network

(2014) J.M.P.A. van den Reek et al.   BRITISH JOURNAL OF DERMATOLOGY

Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

(2014) R. Gniadecki et al.   BRITISH JOURNAL OF DERMATOLOGY

Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry

(2014) C. Medina et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry

(2014) G. Carretero et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study

(2013) M. Esposito et al.   BRITISH JOURNAL OF DERMATOLOGY

Drug survival rates in patients with psoriasis after treatment with biologics

(2013) Yoshinori Umezawa et al.   JOURNAL OF DERMATOLOGY

Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic Therapy

(2012) Gregorio Carretero   ARCHIVES OF DERMATOLOGY

Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data

(2012) M.H.A. Rustin   BRITISH JOURNAL OF DERMATOLOGY

Biologics for psoriasis: current evidence and future use

(2012) C.E.M. Griffiths   BRITISH JOURNAL OF DERMATOLOGY

Drug survival rates of biologic treatments in patients with psoriasis vulgaris

(2011) A.M.G. Brunasso et al.   BRITISH JOURNAL OF DERMATOLOGY

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

(2011) R. Gniadecki et al.   BRITISH JOURNAL OF DERMATOLOGY

The Misperception That Clinical Trial Data Reflect Long-term Drug Safety

(2009) Tamar Nijsten et al.   ARCHIVES OF DERMATOLOGY

British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

(2009) C.H. Smith et al.   BRITISH JOURNAL OF DERMATOLOGY

A new era in the management of psoriasis? The biologics: facts and controversies

(2009) Carlos Ferrándiz et al.   CLINICS IN DERMATOLOGY

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

(2008) J. Schmitt et al.   BRITISH JOURNAL OF DERMATOLOGY